:: Jun-Jul 2008

Welcome to our Monthly Online Newsletter!

View all Treatment articles in our Treatment Report . The most recent articles are listed on top (not in alphabetical order). Click on the Topic on our home page and then the subtopic - Treatment Report. Stay updated on drugs and their side effects, and various other treatments, including exercise, nutrition, and supplements.

NGC - Benign prostatic hyperplasia. (2004)

NGC - Benign prostatic hyperplasia. (2005)

NGC - Benign prostatic hyperplasia. (2006)

NGC - Lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (2005)

Featured site

NIH - Medical Encyclopedia BPH

Benign prostatic hyperplasia (BPH)

NIH - Medical Encyclopedia BPH

NIH - Medical Encyclopedia Enlarged Prostate

NIH - Medical Encyclopedia BPH - Resources

NIH - NIDDK Prostate Enlargement: Benign Prostatic Hyperplasia

NIH - NIDDK What I need to know about Prostate Problems

NIH - Prostate Diseases

Prostate Cancer

Prostate Cancer

Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case--control study in Wayne County, Michigan. (Cancer Causes Control. 2005 ) "CONCLUSIONS: Among all subjects, prostate cancer was associated with prostatitis and BPH history, but not with STD or vasectomy history. Prevention efforts could be enhanced if inflammatory or infectious etiologies are found to be of importance in the subsequent development of prostate cancer."

Prostate Cancer

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. (BJU Int. 2005) "OBJECTIVE: To further analyse the relationship of c-reactive protein (CRP) levels to prostate cancer, by measuring CRP in men with prostate cancer and benign prostatic hypertrophy (BPH), as chronic inflammation has long been linked to cancers with an infectious cause and CRP is a nonspecific marker for inflammation, associated with prostate cancer incidence and progression. ... CONCLUSION: The strong association of CRP with PSA, independent of tumour stage, suggests that inflammation might be fundamental in prostate cancer, and that chronic inflammation may be a legitimate target for prostate cancer chemoprevention and treatment."